Recently published research from Business Monitor International, "Switzerland Pharmaceuticals & Healthcare Report Q2 2017", is now available at Fast Market Research
PR-Inside.com: 2017-05-19 17:06:42
Switzerland has a well-developed healthcare system and pharmaceutical industry with its citizens enjoying extensive access to high quality health services and advanced medicines. We expect the Swiss pharmaceutical market will continue to grow in the coming years, spurred on by an aging population, which favours patented drugs over low-value generics. However, as a result of growing healthcare cost, the government will likely impose further price control mechanisms, targeting innovative medicines in particular.
The Switzerland Pharmaceuticals & Healthcare Report features BMI Research's forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.
BMI's Switzerland Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Switzerland pharmaceutical and healthcare industry.
Full Report Details at
- www.fastmr.com/prod/1275214_switzerland_pharmaceuticals.aspx?afi ..
Benchmark BMI's pharmaceutical and healthcare market forecasts for Switzerland, to test other views - a key input for successful budgeting and strategic business planning in the Swiss pharmaceutical and healthcare market.
Target business opportunities and risks in the Swiss pharmaceutical and healthcare sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in Switzerland.
Assess the activities, strategy and market position of your competitors using our company profiles (including SWOTs, KPIs and latest activity) and competitive landscape tables.
BMI Industry View
An at-a-glance perspective on the latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The pharmaceuticals and healthcare SWOT outlines strategic factors that affect the basic assumptions underpinning BMI�s forecast analysis, and taken together with BMI�s political, economic and business environment SWOTs, it gives a complete overview of market climate.
BMI Industry Forecast Scenario
Industry forecasts to end-2019 for all key indicators, supported by explicit assumptions, plus analysis of key downside risks to the main forecasts:
Healthcare: Total healthcare expenditure (USDbn), healthcare expenditure (% of GDP), healthcare expenditure per capita (USD), hospital beds, doctors, and birth & mortality rates (all per �000 population).
Pharmaceutical Market: Drug expenditure in USDbn, % of GDP and per capita (USD).
Patented Drug Market: Prescription drug sales (USDbn & % of total sales).
Generic Drug Market: Generic product sales (USDbn), generic sales (% of total sales).
OTC Drug Market: OTC sales (USDbn & % of total sales).
Macroeconomic Forecasts: Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against USD, government expenditure and external debt.
BMI�s Pharmaceuticals and Healthcare Risk Reward Index
BMI�s Risk Reward Index provides investors (both national and multinational) looking for opportunities in the region with a clear country-comparative assessment of the market�s risks and potential rewards. Each of the country markets are scored using a sophisticated model that includes more than 40 industry, economic and demographic data points to provide indices of highest to lowest appeal to investors, with each position explained.
A snapshot of key market characteristics, including total size of the pharmaceuticals and healthcare segments, growth drivers, leading therapeutic areas and the competitive landscape
A focus on government healthcare reforms, epidemiological trends, mergers and acquisitions, product launches, market entries, FDI activity, R&D, biotechnology, clinical trials and supply chain issues.
Details of the industry regulatory framework and key legislation covering the licensing of new products/services, pricing and reimbursements, intellectual property, taxation and advertising, as well as analysis of the overall regulatory burden.
The competitive landscape section provides comparative company analyses and index by USD sales and % share of total sales � for the total pharmaceutical sector, as well as the OTC, generics and distribution sub-sectors.
About Business Monitor International
Business Monitor International (BMI) offers a comprehensive range of products and services designed to help senior executives, analysts and researchers assess and better manage operating risks, and exploit business opportunities, across 175 markets. BMI offers three main areas of expertise: Country Risk BMI's country risk and macroeconomic forecast portfolio includes weekly financial market reports, monthly regional Monitors, and in-depth quarterly Business Forecast Reports. Industry Analysis BMI covers a total of 17 industry verticals through a portfolio of services, including in-depth quarterly Country Forecast Reports. View more research from Business Monitor International at www.fastmr.com/catalog/publishers.aspx?pubid=1010&afid=701
About Fast Market Research
Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.
For more information about these or related research reports, please visit our website at www.fastmr.com
or call us at 1.800.844.8156 (1.413.485.7001 Int'l)